# US 2013/0158651 A1 · Porous Bidirectional Bellowed Tracheal Reconstruction Device

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158651 A1
- Document ID: US20130158651A1
- Status: Published application
- Kind: A1
- Application number: 13/715,715
- Filed: 2012-12-14
- Published: 2013-06-20
- Earliest claimed: 2011-12-14
- Assignees: The Regents of the University of Michigan
- Inventors: Scott J. Hollister; Glenn E. Green
- Web page: https://patentgrep.com/patent/US20130158651A1

## CPC

- A61F 2/848: having means for fixation to the vessel wall, e.g. barbs
- A61F 2/94: Stents retaining their form, i.e. not being deformable, after placement in the predetermined place
- A61L 31/005: {Ingredients of undetermined constitution or reaction products thereof}
- A61L 31/06: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {(A61L31/041 takes precedence)}
- A61L 31/148: {Materials at least partially resorbable by the body}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- B29C 64/153: using layers of powder being selectively joined, e.g. by selective laser sintering or melting
- A61F 2002/043: {Bronchi}
- A61F 2002/044: {Oesophagi or esophagi or gullets}
- A61F 2002/046: {Tracheae}
- A61F 2220/0008: Fixation appliances for connecting prostheses to the body
- A61F 2220/0075: sutured, ligatured or stitched, retained or tied with a rope, string, thread, wire or cable
- A61F 2220/0091: connected by a hinged linkage mechanism, e.g. of the single-bar or multi-bar linkage type
- B29K 2067/00: Use of polyesters {or derivatives thereof}, as moulding material
- B29K 2105/251: {Particles, powder or granules (expandable particles B29K2105/046)}
- B29K 2995/0056: Biocompatible, e.g. biopolymers or bioelastomers
- B29L 2031/7534: {Cardiovascular protheses}
- B33Y 10/00: Processes of additive manufacturing
- B33Y 80/00: Products made by additive manufacturing
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- B29C: SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING (making preforms B29B11/00; making laminated products by combining previously unconnected layers which become one product whose layers will remain together B32B37/00 - B32B41/00)
- B29K: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR {MOULDS, } REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29L: INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
- B33Y: ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING

## Abstract

Implantable splinting devices for supporting a passageway defect in a patient that is formed from one or more support structures comprising a polymer or a polymer and acellularized tissue matrix that define a structural component that substantially conforms to a defective passageway of the patient. The structural component also has a plurality of pores. The implantable splinting device is capable of being placed around a trachea, a bronchi, an esophagus and a blood vessel of a patient. The implantable splinting device may also be configured for placement between the trachea and the esophagus of a patient.

## Claims

### Claim 1

An implantable splinting device for supporting a defect in a passageway of a human or other animal subject comprising:
one or more support structures together defining a structural component that substantially conforms to at least a portion of the passageway, wherein the one or more support structures comprise a biomedically acceptable polymeric material;
a longitudinal opening formed within the one or more support structures to facilitate placement of the implantable splinting device over the passageway; and
a plurality of apertures defined in at least a portion of the one or more support structures capable of receiving a suture for attaching the implantable splinting device to at least a portion of the passageway.

### Claim 2 (depends on 1)

The implantable splinting device of claim 1, wherein the implantable splinting device is designed for placement around and substantially conforms to at least a portion of the passageway selected from the group consisting of: a trachea, a bronchi, an esophagus, and a blood vessel.

### Claim 3 (depends on 1)

The implantable splinting device of claim 1, wherein the passageway defect is selected from the group consisting of: tracheomalacia, tracheoesophageal fistula, tracheoinnominate fistula, congenital stenosis, acquired stricture, cancer (obstruction from tumors), idiopathic tracheomalacia, tracheal/airway reconstruction surgery, bronchomalacia, weakened veins and a coronary bypass.

### Claim 4 (depends on 1)

The implantable splinting device of claim 1, wherein the structural component has an inner diameter and an outer diameter, wherein the inner diameter ranges from greater than or equal to about 4 mm to less than or equal to about 30 mm and the outer diameter ranges from greater than or equal to about 5 mm to less than or equal to about 34 mm, and wherein the implantable splinting device has a length ranging from greater than or equal to about 10 mm to less than or equal to about 60 mm.

### Claim 5 (depends on 1)

The implantable splinting device of claim 1, wherein the biomedically acceptable polymeric material comprises a biodegradable polymer.

### Claim 6 (depends on 5)

The implantable splinting device of claim 5, wherein the biodegradable polymer is polycaprolactone.

### Claim 7 (depends on 5)

The implantable splinting device of claim 5, wherein the biodegradable polymer has a degradation time of from about 10 months to about 24 months.

### Claim 8 (depends on 1)

The implantable splinting device of claim 1, wherein the implantable splinting device further comprises a bioactive agent, wherein the bioactive agent is selected from the group consisting of: a cell adhesion factor, an isolated tissue material, a growth factor, a peptide, a cytokine, a hormone, a pharmaceutical active, and combinations thereof.

### Claim 9 (depends on 8)

The implantable splinting device of claim 8, wherein the implantable splinting device comprises acellularized dermis, an acellularized tissue matrix, a composite of acellularized dermis matrix and designed polymer, or a composite of acellularized tissue matrix and designed polymer.

### Claim 10 (depends on 1)

The implantable splinting device of claim 1, wherein the one or more support structures is a plurality of bellows.

### Claim 11 (depends on 10)

The implantable splinting device of claim 10, wherein each bellow of the plurality of bellows has a wave period of greater than or equal to about 1.5 mm to less than or equal to about 6 mm.

### Claim 12 (depends on 11)

The implantable splinting device of claim 11, wherein each bellow of the plurality of bellows comprises a protruding region and a recessed region.

### Claim 13 (depends on 12)

The implantable splinting device of claim 12, wherein a first length of the protruding region is greater than or equal to about 1 mm to less than or equal to about 4 mm and a second length of the recessed region is greater than or equal to about 0.5 mm to less than or equal to about 2 mm.

### Claim 14 (depends on 1)

The implantable splinting device of claim 1, wherein a width of the longitudinal opening ranges from greater than or equal to about 4 mm to less than or equal to about 15 mm.

### Claim 15 (depends on 1)

The implantable splinting device of claim 1, wherein the plurality of apertures respectively has a diameter ranging from about 0.5 mm to about 3 mm.

### Claim 16 (depends on 1)

The implantable splinting device of claim 1, wherein the implantable splinting device comprises a first structural component and a second structural component.

### Claim 17 (depends on 16)

The implantable splinting device of claim 16, wherein the first structural component is a tracheal U-shaped structure and the second structural component is an esophageal U-shaped structure.

### Claim 18 (depends on 16)

The implantable splinting device of claim 16, wherein the first structural component and the second structural component are joined together via a hinge to define the structural component.

### Claim 19

An implantable splinting device for supporting a defect in a passageway of a human or other animal subject comprising:
one or more support structures together defining a structural component that substantially conforms to at least a portion of the passageway and a plurality of apertures defined in at least a portion of the one or more support structures, wherein the one or more support structures comprise a biomedically acceptable polymeric material, so that the structural component is capable of restricting displacement to less than 10% under a direct compression load of about SON, while permitting outward radial displacement of at least 100% of an initial diameter of the structural component under non-stress conditions under a radial pressure of about SON.

### Claim 20 (depends on 19)

The implantable splinting device of claim 19, wherein the biomedically acceptable polymeric material is polycaprolactone and has a degradation time of from about 10 months to about 24 months.

### Claim 21 (depends on 19)

The implantable splinting device of claim 19, wherein the implantable splinting device is designed from a set of medical image data specific to the patient.

### Claim 22

A method of making an implantable splinting device for application to a passageway defect in a human or other animal subject comprising:
designing a structural component for the implantable splinting device from a set of medical image data of the passageway defect specific to the subject;
laser sintering a biomedically acceptable polymeric material to form the structural component; and
integrating a plurality of pores within the structural component capable of receiving a suture for attaching the implantable splinting device to at least a portion of the passageway.

### Claim 23 (depends on 22)

The method of claim 22, wherein the implantable splinting device is configured for placement around at least a portion of the passageway of the subject selected from the group consisting of: a trachea, a bronchi, an esophagus and a blood vessel.

### Claim 24 (depends on 22)

The method of claim 22, wherein the biomedically acceptable polymeric material is polycaprolactone and has a degradation time of from about 10 months to about 24 months.

### Claim 25

A method of making an implantable splinting device for application to a defect in a passageway of a human or other animal subject comprising:
forming a biomedically acceptable polymeric material into a U-shaped structural component comprising a plurality of apertures and a plurality of bellows, wherein the U-shaped structural component substantially conforms to at least a portion of the passageway selected from the group consisting of a trachea, a bronchi, an esophagus and a blood vessel.

### Claim 26 (depends on 25)

The method of claim 25, wherein the biomedically acceptable polymeric material is polycaprolactone and has a degradation time of from about 10 months to about 24 months.
